Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Hernia ; 23(5): 987-994, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-30430273

RESUMEN

PURPOSE: Increasingly, radiologic imaging is obtained as part of the pathway in diagnosing ventral hernias. Often, radiologists receive incomplete or incorrect clinical information from clinicians. OBJECTIVE: The aim of the study is to determine if clinical exam findings alter radiological interpretation of ventral hernias on CT. METHODS: This is a single-institution double-blind, randomized trial. All patients with a recent abdominal/pelvic CT scan seen in various surgical clinics were enrolled. A surgeon blinded to the CT scan findings performed a standardized physical examination and assessed for the presence of a ventral hernia. Seven independent radiologists blinded to the study design reviewed the scans. Each radiologist received one of three types of clinical exam data per CT: accurate (correct), inaccurate (purposely incorrect), or none. Allocation was random and stratified by the presence of clinical hernia. The primary outcome was the proportion of radiologic hernias detected, analyzed by chi square. RESULTS: 115 patients were enrolled for a total of 805 CT scan reads. The proportion of hernias detected differed by up to 25% depending on if accurate, no, or inaccurate clinical information was provided. Inaccurate clinical data in patients with no hernia on physical exam led to a significant difference in the radiologic hernia detection rate (54.3% versus 35.7%, p = 0.007). No clinical data in patients with a hernia on physical exam led to a lower radiologic hernia detection rate (75.0% versus 93.8%, p = 0.001). CONCLUSIONS: The presence and accuracy of clinical information provided to radiologists impacts the diagnosis of abdominal wall hernias in up to 25% of cases. Standardization of both clinical and radiologic examinations for hernias and their reporting are needed. TRIAL REGISTRATION: Clinicaltrials.gov, Number NCT03121131, https://clinicaltrials.gov/ct2/show/NCT03121131.


Asunto(s)
Errores Diagnósticos/prevención & control , Hernia Ventral , Radiografía Abdominal/métodos , Tomografía Computarizada por Rayos X , Método Doble Ciego , Femenino , Hernia Ventral/diagnóstico , Hernia Ventral/cirugía , Humanos , Masculino , Persona de Mediana Edad , Examen Físico/métodos , Examen Físico/normas , Radiólogos/estadística & datos numéricos , Reproducibilidad de los Resultados , Cirujanos/estadística & datos numéricos , Tomografía Computarizada por Rayos X/métodos , Tomografía Computarizada por Rayos X/normas
2.
J Pharm Sci ; 64(3): 528-34, 1975 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-239196

RESUMEN

Thirteen pyridine compounds, phenylbutazone, and three salicylates were studied for their effects upon the turnover of 7-14C-nicotinamide dinucleotides in the mouse. The compounds were administered at equitoxic doses (LD25) to 7-14C-nicotinic acid- (niacin) pretreated mice, and the induced excretion of urinary-14C was analyzed in terms of total 14C and percentage of total 14C as known metabolites of nicotinic acid. Of the 17 compounds, 12 afforded significant alterations in the total 14C excreted and five of these caused alterations in the disposition of the 7-14C-nicotinamide endogenously liberated from the 7-14C-nicotinamide adenine dinucleotide pool. Comparative depletions of 14C from brain, lungs, liver, and kidneys were studied with 10 of the pyridine compounds. Several tissues were found to be the sources of the urinary-14C, with the lungs being the most accessible source. Some compounds had effects at doses less than the LD25's, as shown by increased hexobarbital sleeping time in acute experiments with rats. These pyridine compounds were initially considered to act at the level of the nicotinamide dinucleotides in the normal biosynthetic pathway (nicotinic acid site) and/or at the level of glycohydrolase (nicotinamide site). In view of the inclusion of nicotinic acid, nicotinamide, salicylic acid, and phenylbutazone in this correlation between toxicity and 7-14C-nicotinamide mobilization, it is not necessary that the formation of compounds analogous to the nicotinamide dinucleotides plays a significant role in the toxic manifestations of the nicotinamide analogs. The displacement of 7-14C-nicotinamide dinucleotides from their corresponding apoenzymes with subsequent metabolism of the dinucleotides could explain the noted increased 7-14C-nicotinamide dinucleotide turnover and depletion which led to the toxic effects.


Asunto(s)
Coenzimas/metabolismo , Niacinamida/toxicidad , Ácidos Nicotínicos/farmacología , Animales , Femenino , Hexobarbital/farmacología , Dosificación Letal Mediana , Ratones , Actividad Motora/efectos de los fármacos , NADP/metabolismo , Niacinamida/análogos & derivados , Nucleótidos/metabolismo , Ratas , Sueño/efectos de los fármacos , Factores de Tiempo
5.
Arch Phys Med Rehabil ; 82(5): 633-6, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11346840

RESUMEN

OBJECTIVE: To determine whether a simple educational intervention can influence use of prescription medications at an institution. DESIGN: Cost-effectiveness analysis of prescribing behavior before and after an educational intervention. SETTING: A large, urban, free-standing academic rehabilitation hospital. PARTICIPANTS: Physicians, residents, and physician extenders. INTERVENTIONS: The hospital's pharmacy department provided simple written educational material about cost differences of various prescription medications to attending and resident physicians, nurse leaders, and case managers. Telephoned reminders were given when targeted medications were prescribed. MAIN OUTCOME MEASURES: Total prescription medication use was recorded monthly for 12 months before and after the intervention. Pharmaceuticals monitored were subcutaneously administered anticoagulants, histamine type 2 (H2) blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs). RESULTS: A 32% decrease in use of the more costly anticoagulant and a 20% increase in use of the less costly anticoagulant (p <.0001), representing an estimated annual savings of nearly $66,000. Use of more costly H2 antagonist decreased 50% and use of less costly H2 antagonist increased 128% (p <.0001). With written intervention only, use of more costly NSAIDs declined 28%, whereas use of less costly NSAIDs increased 58% (p <.0020). CONCLUSION: Providing physicians with simple pharmaceutical cost information and telephone reminders decreased the use of targeted more costly medications.


Asunto(s)
Costos de los Medicamentos , Prescripciones de Medicamentos/economía , Educación Médica/normas , Conocimientos, Actitudes y Práctica en Salud , Anticoagulantes/economía , Análisis Costo-Beneficio , Prescripciones de Medicamentos/normas , Enoxaparina/economía , Famotidina/economía , Antagonistas de los Receptores H2 de la Histamina/economía , Humanos , Pautas de la Práctica en Medicina/economía
6.
Radiographics ; 6(3): 373-99, 1986 May.
Artículo en Inglés | MEDLINE | ID: mdl-3317544

RESUMEN

Radiology is valuable in determining the cause of pacemaker malfunction and in the evaluation of lead position and integrity.


Asunto(s)
Marcapaso Artificial , Angiografía , Cineangiografía , Electrodos Implantados , Falla de Equipo , Humanos , Imagen por Resonancia Magnética , Radiografía Torácica , Ultrasonografía
7.
Radiology ; 192(1): 33-6, 1994 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8208960

RESUMEN

PURPOSE: To assess the efficacy of perioperative implantation of iridium-192 for stage I and II breast cancer. MATERIALS AND METHODS: The authors retrospectively reviewed findings from 655 patients with stage I and II cancer treated with conservative surgery and Ir-192 implantation between 1982 and 1992. Hollow plastic tubes were placed in the tumor bed as a single- or double-plane implant at lumpectomy. Ribbons with Ir-192 seeds were inserted into the tubes 4-6 hours later. The Ir-192 was left in place for approximately 50 hours. External-beam irradiation was given to the whole breast 10-14 days later. RESULTS: Follow-up ranged from 2 to 146 months. The local control at 10 years for stage I and II disease was 93% and 87%, respectively. The 10-year actuarial survival rate was 92% +/- 1 for stage I disease and 72% +/- 4 for stage II disease. The rate of survival with no evidence of disease for stage I and II disease combined was 82% +/- 1 at 5 years and 75% +/- 3 at 10 years. CONCLUSION: Perioperative implantation produced excellent local control equal to that with electron-beam therapy.


Asunto(s)
Braquiterapia , Neoplasias de la Mama/radioterapia , Radioisótopos de Iridio/uso terapéutico , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/cirugía , Terapia Combinada , Femenino , Humanos , Mastectomía Segmentaria , Persona de Mediana Edad , Estudios Retrospectivos , Tasa de Supervivencia
8.
Cancer ; 75(9): 2328-36, 1995 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-7712444

RESUMEN

BACKGROUND: One thousand seventy patients treated conservatively for Stages I and II breast cancer between the years 1982 and 1994 were reviewed. The median follow-up was 40 months with a maximum follow-up of 152 months. METHODS: All patients had a wide local excision and lower lymph axillary node dissection followed by radiation therapy. The entire breast received an external beam dose of 4500 cGy at 180 cGy/5 days/week. An additional boost dose of 2000 cGy to the tumor bed was given at the time of lumpectomy (perioperative) with an Ir-192 implant or with electron beam therapy after the external beam therapy. RESULTS: The 5- and 10-year disease specific survival results were 97 and 90%, respectively for Stage I and 87 and 69% for patients with Stage II disease. The 5- and 10-year local control rates were 93 and 85% for Stage I and 92 and 87% for Stage II, respectively. The risk factors for local failure were premenopausal status and estrogen receptor-negative status at the univariate level but at the multivariate level the premenopausal and margins status were significant. CONCLUSION: These 10-year results were at least equivalent to reported series of similarly staged patients treated by mastectomy. This should encourage more surgeons to offer conservative treatment as an alternative to mastectomy to patients with Stage I and II breast cancer.


Asunto(s)
Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/radioterapia , Carcinoma Ductal de Mama/cirugía , Braquiterapia , Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/patología , Terapia Combinada , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Radioisótopos de Iridio/uso terapéutico , Escisión del Ganglio Linfático , Mastectomía , Mastectomía Segmentaria , Persona de Mediana Edad , Análisis Multivariante , Recurrencia Local de Neoplasia/prevención & control , Estadificación de Neoplasias , Premenopausia , Dosificación Radioterapéutica , Radioterapia de Alta Energía , Receptores de Estrógenos/análisis , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA